je.st
news
Tag: insulin
16 Indiana students given insulin during tuberculosis test
2019-09-30 23:08:00| American School & University
Students at the McKenzie Center for Innovation and Technology in the Lawrence Township (Ind.) district were mistakenly given a small dose of insulin.
Tags: test
students
indiana
insulin
Insulin Pump Susceptible to Hacking
2016-10-07 18:00:00| TechNewsWorld
Medical device manufacturer Animas on Tuesday warned that its OneTouch Ping insulin pump system was susceptible to hacking. "We have been notified of a cybersecurity issue with the OneTouch Ping, specifically that a person could potentially gain unauthorized access to the pump through its unencrypted radio frequency communication system," reads the company's letter to users of the device.
Tags: pump
susceptible
hacking
insulin
Johnson & Johnson says insulin pump 'could be hacked'
2016-10-04 19:00:45| BBC News | Business | UK Edition
Pharmaceutical firm Johnson & Johnson says one of its insulin pumps risks being hacked, causing a diabetic overdose.
Tags: johnson
pump
insulin
hacked
Merck Announces U.S. FDA Filing Acceptance of New Drug Application (NDA) for MK-1293, an Investigational Follow-On Biologic Insulin Glargine
2016-08-05 14:00:00| Merck.com - Research & Development News
Dateline City: KENILWORTH, N.J. Marketing Authorization Application to the European Medicines Agency Currently Under Review KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for MK-1293, an investigational follow-on biologic1 insulin glargine candidate for the treatment of people with type 1 and type 2 diabetes, which is being developed by Merck with partial funding from Samsung Bioepis. Language: English Contact: MerckMedia:Doris Li, 908-246-5701orKristen Drake, 908-236-4223orInvestors:Amy Klug, 908-740-1898 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: application
drug
acceptance
filing
Mercks Investigational Insulin Glargine, MK-1293, Met Primary Endpoint in Two Phase 3 Studies, Showing Non-Inferiority to Lantus
2016-06-13 16:30:00| Merck.com - Research & Development News
Dateline City: KENILWORTH, N.J. Data in Patients with Type 1 and Type 2 Diabetes Presented for the First Time at the 76 th Scientific Sessions of the American Diabetes Association KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced results from two Phase 3 studies evaluating MK-1293, Mercks investigational, follow-on biologic* insulin glargine candidate for the treatment of people with type 1 and type 2 diabetes. Language: English Contact: MerckMedia:Doris Li, 908-246-5701Kristen Drake, 908-334-4688orInvestor:Justin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more